Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
A BCMA-targeting combo keeps outperforming the competition. Four-year follow-up data from the DREAMM-7 trial show that belantamab mafodotin (belamaf) plus bortezomib and dexamethasone (BVd) continues to deliver superior survival over the standard anti-CD38 triplet in relapsed/refractory multiple myeloma. Median overall survival was not yet reached in the BVd group, versus 35.7 months for the comparator — a compelling case for a new standard of care.
A BCMA-targeting combo keeps outperforming the competition
Four-year follow-up data from the phase 3 DREAMM-7 trial confirm that the belantamab mafodotin (belamaf), bortezomib, and dexamethasone (BVd) triplet delivers durable, superior survival over the anti-CD38–containing regimen daratumumab, bortezomib, and dexamethasone (DVd) in patients with relapsed/refractory multiple myeloma (RRMM). Presented at the SOHO 2026 Annual Meeting, the results held across both the intent-to-treat population and the heavily pretreated subgroup with 3+ prior lines of therapy.
Complementary data from the DREAMM-8 trial (presented at ASCO 2026) add further weight: belamaf-treated patients were more than 5 times as likely to achieve sustained MRD negativity for at least 12 months compared to bortezomib — and 100% of patients with sustained MRD negativity remained progression-free at 24 months, regardless of treatment arm.
By the Numbers
Why it matters: With a manageable safety profile, stable quality of life, and outpatient administration, BVd is building a strong case as the new BCMA-targeted standard of care for RRMM at first relapse or later.
